Ono Pharmaceutical Co. (OTCMKTS:OPHLF) Short Interest Up 51.3% in July

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totaling 3,578,303 shares, a growth of 51.3% from the July 15th total of 2,365,389 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily volume of 483 shares, the days-to-cover ratio is currently 7,408.5 days.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Stock Performance

Shares of OTCMKTS OPHLF remained flat at $14.71 during mid-day trading on Tuesday. The company has a market cap of $6.91 billion, a PE ratio of 14.01 and a beta of 0.33. The stock’s 50-day simple moving average is $14.39 and its 200 day simple moving average is $14.80. Ono Pharmaceutical has a twelve month low of $10.27 and a twelve month high of $18.67. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research?based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.